A5003543916- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Immune responses and vaccinations
- Inflammatory Bowel Disease
- Cancer Immunotherapy and Biomarkers
- SARS-CoV-2 detection and testing
- Immunotherapy and Immune Responses
- Vaccine Coverage and Hesitancy
- vaccines and immunoinformatics approaches
- COVID-19 and healthcare impacts
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- Biosimilars and Bioanalytical Methods
- Healthcare cost, quality, practices
- Eosinophilic Esophagitis
- NF-κB Signaling Pathways
- Cardiac, Anesthesia and Surgical Outcomes
- Pharmaceutical studies and practices
- Long-Term Effects of COVID-19
Duke-NUS Medical School
2021-2024
University of Göttingen
2018
Universitätsmedizin Göttingen
2018
RNA vaccines against coronavirus disease 2019 (COVID-19) have demonstrated ∼95% efficacy in phase III clinical trials. Although complete vaccination consisted of 2 doses, the onset protection for both licensed was observed as early 12 days after a single dose. The adaptive immune response that coincides with this could represent necessary elements immunity COVID-19.
Defining the correlates of protection necessary to manage COVID-19 pandemic requires analysis both antibody and T cell parameters, but complexity traditional tests limits virus-specific measurements. We tested sensitivity performance a simple rapid SARS-CoV-2 spike protein–specific test based on stimulation whole blood with peptides covering protein, followed by cytokine (IFN-γ, IL-2) measurement in different cohorts including BNT162b2-vaccinated individuals (n = 112), convalescent...
BACKGROUNDPatients undergoing immune-modifying therapies demonstrate a reduced humoral response after COVID-19 vaccination, but we lack proper evaluation of the effect such on vaccine-induced T cell responses.METHODSWe longitudinally characterized and spike-specific responses in patients with inflammatory bowel disease (IBD), who were antimetabolite therapy (azathioprine or methotrexate), TNF inhibitors, and/or other biologic treatment (anti-integrin anti-p40) for up to 6 months completing...
Hybrid immunity to SARS-CoV-2, resulting from both vaccination and natural infection, remains insufficiently understood in paediatric populations, despite increasing rates of breakthrough infections among vaccinated children.
Abstract Background and Aims Inflammatory bowel diseases are linked to an increased risk of developing colorectal cancer [CRC]. Previous studies suggested that the H2B ubiquitin ligase RING finger protein-20 [RNF20] inhibited inflammatory signaling mediated by nuclear factor kappa-light-chain-enhancer activated B cells [NF-κB]. However, role RNF40, obligate heterodimeric partner RNF20, in context inflammation CRC has not been addressed. Here, we examined effect RNF40 loss on vitro vivo....
RNA vaccines against Covid-19 have demonstrated ~95% efficacy in Phase III clinical trials. Although complete vaccination consisted of two-doses, the onset protection for both licensed was observed as early 12 days after a single dose. The adaptive immune response that coincides with this could represent necessary elements immunity Covid-19. Herein, we tracked responses vaccination, cohort 20 healthcare workers. Our findings suggest T cell and binding antibody responses, rather than either...
An accurate depiction of the convalescent COVID-19 immunome will help delineate immunological milieu crucial for disease resolution and protection. Using mass cytometry, we characterized immune architecture in patients recovering from mild COVID-19. We identified a virus-specific rheostat composed an effector T (T eff ) cell recall response that is balanced by enrichment highly specialized regulatory reg subset. Both components were reactive against peptide pool covering receptor binding...
Abstract The amino acid (AA) mutations that characterise the different variants of concern (VOCs), which replaced ancestral SARS-CoV-2 Wuhan-Hu-1 isolate worldwide, provide biological advantages such as increased infectivity and partial escape from humoral immunity. Here we analysed impact these on vaccination- infection-induced Spike-specific T cells. We confirmed that, in majority infected or vaccinated individuals, present a single VOC (Delta) combined mosaic more than 30 AA substitutions...
Abstract Background Antibodies and T cells cooperate to control virus infections. The definition of the correlates protection necessary manage COVID-19 pandemic, require both immune parameters but complexity traditional tests limits virus-specific cell measurements. Methods We test sensitivity performance a simple rapid SARS-CoV-2 Spike-specific based on stimulation whole blood with peptides covering Spike protein followed by cytokine (IFN-γ, IL-2) measurement in different cohorts including...
Abstract Background The expanding therapeutic armamentarium for inflammatory bowel disease (IBD) has drastically improved the clinical outcomes of patients with both Crohn’s Disease (CD), and Ulcerative Colitis (UC). However, data in newly diagnosed IBD era biologics recent decades remains limited. We aim to compare Singapore between conventional (originator Anti-TNF) those during newer over a 14-year period. Methods This is multi-centre retrospective observational cohort study. Baseline...
ABSTRACT Patients undergoing immune-modifying therapies demonstrate a reduced humoral response after COVID-19 vaccination, but we lack proper evaluation of the impact such on vaccine-induced T cell responses. Here, longitudinally characterised and Spike-specific responses in inflammatory bowel disease (IBD) patients who are antimetabolite therapy (azathioprine or methotrexate), TNF inhibitors and/or other biologic treatment (anti-integrin anti-p40) mRNA vaccination up to 3 months completing...